EUCTR2015-004134-95-GB进行中（未招募）1 期
Phase II clinical study of concurrent PAzopanib for non-metastatic SArcoma patients to be treated with RadioTherapy, localized in the extremities, trunk and chest wall or the head and neck region. - PASART 2
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically confirmed newly diagnosed intermediate to high grade soft tissue sarcoma localized to the extremities, trunk and chest wall or the head and neck area, for which the standard treatment is a combination of and radiotherapy and surgery(deep seated, > 5cm according to the RECIST 1.1 criteria and/or an anticipated close resection margin, grade II/III according to the FNLCC definition)
- •Age = 18 years
- •WHO performance status of = 1
- •Able and willing to undergo blood sampling for PK and PD analysis
- •Able to swallow and retain oral medication
- •Able and willing to undergo MRI scanning
- •Able and willing to undergo tumor biopsies
- •Adequate organ functions as described by the laboratory findings in the table 1. For thyroid function, the T4 and TSH values must be within normal values of the range of the participating centers
- •Written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •Prior malignancies; except another malignancy and disease-free for = 5 years, or completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma.
- •Patients with recurrent sarcomas (even without prior radiotherapy)
- •Ewing sarcoma and other PNET family tumors, rhabdomyosarcomas (both pediatric and adult), osteosarcomas
- •Clinically significant gastrointestinal abnormalities which might interfere with oral dosing diagnosed as:
- •?Active peptic ulcer disease
- •?Inflammatory bowel disease, ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation
- •?History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment
- •?Major resection of the stomach or small bowel
- •Poorly controlled hypertension [defined as systolic blood pressure (SBP) of =140 mmHg or diastolic blood pressure (DBP) of = 90mmHg]
- •Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. Following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals. At least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement. These three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure. The mean SBP / DBP ratio must be <140/90 mmHg (or 150/90 mm Hg, if this criterion is approved by the Principal Investigator) in order for a subject to be eligible for the study.
- •Unstable or serious concurrent condition (e.g., active infection requiring systemic therapy)
- •Prolongation of corrected QT interval (QTc) > 480 msecs on ECG
- •History of any of more of the following cardiovascular conditions within the past 6 months:
- •?Cardiac angioplasty or stenting
- •?Myocardial infarction
- •?Unstable angina
- •?Symptomatic peripheral vascular disease
- •?Coronary artery by-pass graft surgery
- •?Class II, III or IV congestive heart failure as defined by the New York Heart Association (NYHA)
- •?History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
- •Macroscopic hematuria
- •Hemoptysis that is clinically relevant within 4 weeks of first dose of pazopanib
- •Evidence of active bleeding or bleeding diathesis
- •Prior major surgery or trauma within 28 days prior to first dose of study medication and/or presence of any non-healing wound, fracture, or ulcer
- •Chemotherapy or radiation therapy within 2 weeks prior to the first dose of study medication
- •Biological therapy or treatment with an investigational agent within 28 days or five half-lives, whichever is longer prior to the first dose of study medication
- •Prohibited medications listed in the protocol for 14 days or five half-lives of a drug (whichever is longer) prior to visit 1 and for the duration of the study
- •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth
研究者
相似试验
进行中（未招募）
不适用
Fase II onderzoek waarin de effectiviteit van 800 mg pazopanib in tabletvorm toegevoegd aan de standaard 25x bestraling wordt onderzocht, bij patiënten met weke delen tumoren in de armen of benen, de borstkas of buikwand en het hoofd/hals gebied (PASART-2)Phase II study to investigate the efficacy of adding 800 mg oral pazopanib to standard 25 x 2 Gy radiotherapy at patients with non-metastatic SArcoma patients lokalized in the extremities, trunk and chest wall or in the head and neck regionon-metastatic sarcoma patients localized in the extremities, trunk and chest wall or the head and neck regionMedDRA version: 18.1Level: PTClassification code 10039491Term: SarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10039492Term: Sarcoma boneSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004134-95-NLThe Netherlands Cancer Institute35
已完成
2 期
Phase II clinical study of concurrent Pazopanib for non-metastatic Sarcoma patients to be treated with Radiotherapy, localized in the extremities, trunk and chest wall or the head and neck region.soft tissue tumor10028389sarcomaNL-OMON47205Antoni van Leeuwenhoek Ziekenhuis27
进行中（未招募）
不适用
A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study)GlioblastomaEUCTR2014-001578-32-FRCENTRE ANTOINE LACASSAGNE51
已完成
2 期
Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcomarelapsed or metastatic soft tissue sarcomaC49Malignant neoplasm of other connective and soft tissueDRKS00003139niversitätsklinikum Halle (Saale)90
进行中（未招募）
1 期
Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcomaEUCTR2009-017261-32-DEMartin-Luther-Universität Halle-Wittenberg